<DOC>
	<DOCNO>NCT00778544</DOCNO>
	<brief_summary>The objective study compare rate extent absorption Ranbaxy Laboratories Limited , India , Amoxicillin-Clavulanic acid GlaxoSmithKline , U.S.A. ( Augmentin ES-600 ) , amoxicillin-clavulanic acid , administer 1 x 5 mL ( 600 mg - 42.9 mg ) oral suspension , feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Amoxicillin-Clavulanic Acid 600 mg-42.9 mg/ 5 mL Oral Suspension Under Fed Conditions</brief_title>
	<detailed_description>This single center , randomize , single-dose , open label , 2 - way crossover bioequivalence study compare rate extent absorption test amoxicillin-clavulanic acid versus Augmentin ES-600 , reference amoxicillin- clavulanic acid , fed condition . Prior study commencement , subject randomly assign treatment accordance randomization scheme generate Anapharm . Subjects confine Anapharm Clinical research Facility least 11 hour prior drug administration 12.0 hour post-dose blood draw , period . The treatment phase separate washout period 14 day . A total sixty-two ( 62 ) healthy adult subject sign study specific inform consent form confine period I ; subject forty eight ( 48 ) , ( 21 male 27 female ) enrol dosed study ; forty six ( 46 ) enrol subject complete clinical phase study</detailed_description>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<criteria>Subjects enrol study member community large . The recruitment advertisement may use various medium type ( e.g . radio , newspaper , SFBP Anapharm Web site , SFBC Anapharm Volunteers database ) . Subjects must meet follow criterion include study : 1 . Male female , smoker nonsmoker , 18 year age old 2 . Capable consent 3 . BMI great equal 19.0 less 30.0 Subjects follow applies exclude study : 1 . Clinically significant illness surgery within 4 week prior dose 2 . Any clinically significant abnormality abnormal laboratory test result find medical screen 3 . Any reason opinion clinical SubInvestigator , would prevent subject participate study 4 . Positive test hepatitis B , hepatitis C , HIV screen 5 . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mm Hg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screen 6 . History significant alcohol abuse drug abuse within one year prior screen visit 7 . Regular use alcohol within six month prior screen visit ( 14 unit alcohol per week [ 1 unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) 8 . Use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior screen 9 . History allergic reaction amoxicillinclavulanic acid , penicillin , relate drug 10 . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , Omeprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolines , antihistamine ) within 30 day prior administration study medication 11 . Use investigational drug participation investigational study within 30 day prior dose 12 . Clinically significant history presence gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug . 13 . Any clinically significant history presence neurological , endocrinal , cardiovascular , pulmonary , hematological , immunologic , psychiatric , metabolic disease . 14 . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption hormonal contraceptive 15 . Difficulty swallow study medication 16 . Smoking 25 cigarette per day 17 . Any food allergy , intolerance , restriction special diet , opinion Clinical SubInvestigator , could contraindicate subject 's participation study 18 . A depot injection implant drug ( hormonal contraceptive ) within 3 month prior administration study medication 19 . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 499 mL whole blood within 30 day More 499 mL whole blood within 56 day prior drug administration 20 . Wear denture presence brace time dose pierce mouth , lip , and/ tongue 21 . Positive urine pregnancy test screen 22 . Breast feed subject 23 . Female subject childbearing potential unprotected sexual intercourse nonsterile male partner ( i.e . male sterilized vasectomy least 6 month ) within 14 day prior study drug administration . Hormonal contraceptive permit study acceptable method contraception . Acceptable method contraceptive : Intrauterine contraceptive device ( place least 4 week prior study drug administration Condom diaphragm + spermicide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence amoxicillin-clavulanic acid 600 mg 42.9 mg per 5 mL oral suspension</keyword>
</DOC>